• 04_02 Adjuvant Options for Prostate Cancer

  • Jan 8 2024
  • Duración: 29 m
  • Podcast

04_02 Adjuvant Options for Prostate Cancer

  • Resumen

  • 1. Physiology, efficacy and toxicities of androgen deprivation
    2. Evidence for adjuvant intervention after definitive surgery or radiation
    3. Role of abiraterone in high-risk localized prostate cancer
    4. Limited evidence to support definitive salvage approach

    Citations

    As always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com. We highly encourage review of guidelines published by ASCO, ESMO and other organizations local to your practice.

    DeVita, Vincent T., Jr., Theodore S. Lawrence, and Steven A. Rosenberg. Devita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology. 10th edition. Philadelphia: Wolters Kluwer, 2015.

    Uptodate.com Waltham, MA: Wolters Kluwer.


    1. Attard G et al. Lancet. 2022;399(10323):447-460. doi:10.1016/S0140-6736(21)02437-5

    2. Xie W et al. J Clin Oncol. 2017;35(27):3097-3104. doi:10.1200/JCO.2017.73.9987

    3. Bolla M et al.. NEJM. 2009;360(24):2516-2527. doi:10.1056/NEJMOA0810095/

    4. Kishan AU et al. Lancet Oncol. 2022;23(2):304-316. doi:10.1016/S1470-2045(21)00705-1

    5. Bolla M et al. Lancet. 2002;360(9327):103-108. doi:10.1016/S0140-6736(02)09408-4

    6. Bolla M et al. Lancet Oncol. 2010;11(11):1066-1073. doi:10.1016/S1470-2045(10)70223-0

    7. Bolla M et al. NEJM. 2009;360(24):2516-2527. doi:10.1056/NEJMOA0810095/

    8. Hanks GE et al. J Clin Oncol. 2003;21(21):3972-3978. doi:10.1200/JCO.2003.11.023

    9. Bolla M et al. Lancet. 2002;360(9327):103-108. doi:10.1016/S0140-6736(02)09408-4

    10. Huggins C, Hodges C V. CA Cancer J Clin. 1972;22(4):293-297. doi:10.3322/CANJCLIN.22.4.232

    11. Huggins C et al. Arch Surg. 1941;43(2):209-223. doi:10.1001/archsurg.1941.01210140043004

    12. Rosenthal SA et al. J Clin Oncol. 2019;37(14):1159-1168. doi:10.1200/JCO.18.02158

    Disclosures

    Talking about Tumors with Ryan and Ryann is not medical advice. We have received no funding in relation to the information discussed within this episode and have no financial conflicts of interest to disclose. All opinions are those of whoever stated them. We have compiled this podcast to serve as an introduction to the field of medical oncology for post-graduate trainees interested in the topic.

    Tags

    Hematology/Oncology, evidence based medicine, education, chemotherapy, immunotherapy, medical oncology

    Más Menos
activate_WEBCRO358_DT_T2

Lo que los oyentes dicen sobre 04_02 Adjuvant Options for Prostate Cancer

Calificaciones medias de los clientes

Reseñas - Selecciona las pestañas a continuación para cambiar el origen de las reseñas.